Patents by Inventor Lior Zangi
Lior Zangi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240100188Abstract: Provided is a system for regulating expression of a gene of interest in a target cell, including a recombinant first RNA molecule with (i) a coding sequence for a translation-suppressor protein and (ii) a first microRNA (miR) recognition element in its 3? UTR, wherein the first miR recognition element recognizes a first miR and binding of a first miR to the first miR recognition element reduces translation of the translation suppressor, and a recombinant second RNA molecule, with (i) a coding sequence for the gene of interest, (ii) a recognition sequence for the translation-suppressor, wherein binding of the translation-suppressor to the recognition sequence for the translation-suppressor reduces translation of the gene of interest, and, optionally, (iii) a second miR recognition element in its 3? UTR, wherein the second miR recognition element recognizes one or more second miR and binding of one or more of the one or more second miR to the second miR recognition element reduces translation of the gene of intType: ApplicationFiled: July 10, 2023Publication date: March 28, 2024Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Lior ZANGI, Keerat KAUR, Magdalena ZAK
-
Publication number: 20230008266Abstract: The present application relates to a nucleic acid molecule comprising a first nucleic acid sequence comprising at least a portion of a 5? untranslated region (5? UTR) of a carboxylesterase gene and a second nucleic acid sequence encoding a protein of interest, where the second nucleic acid sequence is heterologous to and operatively coupled to the first nucleic acid sequence. Also disclosed are methods of expressing a protein of interest in a target cell, methods of treating subject for cardiac ischemia or hepatic ischemia, and methods of identifying a nucleic acid sequence capable of selectively enhancing translation of a heterologous protein of interest in a target cell.Type: ApplicationFiled: November 6, 2020Publication date: January 12, 2023Applicant: Icahn School of Medicine at Mount SinaiInventors: Lior Zangi, Yoav Hadas, Nishat Sultana
-
Publication number: 20220347204Abstract: The present disclosure generally relates to compositions and methods of use thereof for treating heart failure encompassing administering a composition of modified mRNA (modRNA) encoding for type 2 phosphatidylinositol-5-phosphate 4-kinase gamma (pip4k2c) to heart tissue of a subject in need thereof.Type: ApplicationFiled: November 11, 2020Publication date: November 3, 2022Inventors: Lior ZANGI, Ajit MAGADUM
-
Publication number: 20220339246Abstract: The present disclosure relates to compositions including molecules of modified mRNA encoding GATA Binding Protein 4, modRNA encoding Myocyte Enhancer Factor 2C, modRNA encoding T-box 5, modRNA encoding Heart- and neural crest derivatives-expressed protein 2, modRNA encoding dominant negative transforming growth factor beta, and modRNA encoding domimant negative Wingless-related integration site 8a, wherein said molecules of modRNAs are present in said composition in a ratio. The present disclosure further relates to pharmaceutical compositions, methods for increasing a ratio of a number of cardiomyocytes to a number of non-cardiomyocytes within a population of cells, methods for treating cardiac injury, methods for stimulating vascular regeneration, methods for treating of stroke, and methods for enhancing wound healing.Type: ApplicationFiled: September 11, 2020Publication date: October 27, 2022Inventors: Lior ZANGI, Keerat KAUR
-
Publication number: 20220220501Abstract: Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion.Type: ApplicationFiled: March 28, 2022Publication date: July 14, 2022Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Lior ZANGI, Ajit MAGADUM
-
Patent number: 11299749Abstract: Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion.Type: GrantFiled: March 15, 2019Date of Patent: April 12, 2022Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Lior Zangi, Ajit Magadum
-
Publication number: 20210000975Abstract: The present disclosure pertains to the use of a modified RNA (modRNA) that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the (modRNA) reduces high levels of ceramide in the cell that lead to cell death or senescence.Type: ApplicationFiled: March 7, 2019Publication date: January 7, 2021Inventors: Efrat ELIYAHU, Lior ZANGI, Adam VINCEK, Yoav HADAS
-
Publication number: 20210002668Abstract: The present disclosure pertains to the use of a modified RNA (modRNA) that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the (modRNA) reduces high levels of ceramide in the cell that lead to cell death or senescence.Type: ApplicationFiled: March 7, 2019Publication date: January 7, 2021Inventors: Efrat ELIYAHU, Lior ZANGI, Adam VINCEK, Yoav HADAS
-
Publication number: 20200000881Abstract: Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyoctes, and tumors.Type: ApplicationFiled: July 23, 2019Publication date: January 2, 2020Applicants: THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Kenneth R. Chien, Leon M. Ptaszek, Kathy Oi-Lan Lui, Lior Zangi, Wataru Ebina, Derrick J. Rossi
-
Publication number: 20190203226Abstract: Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion.Type: ApplicationFiled: March 15, 2019Publication date: July 4, 2019Applicant: ICHAN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Lior ZANGI, Ajit MAGADUM
-
Publication number: 20190117733Abstract: Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyoctes, and tumors.Type: ApplicationFiled: June 22, 2018Publication date: April 25, 2019Applicants: THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Kenneth R. Chien, Leon M. Ptaszek, Oi-Lan Lui, Lior Zangi, Wataru Ebina, Derrick J. Rossi
-
Patent number: 10086043Abstract: Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyoctes, and tumors.Type: GrantFiled: March 12, 2012Date of Patent: October 2, 2018Assignees: THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Kenneth R. Chien, Leon M. Ptaszek, Oi-Lan Lui, Lior Zangi, Wataru Ebina, Derrick J. Rossi
-
Publication number: 20140073687Abstract: Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyoctes, and tumors.Type: ApplicationFiled: March 12, 2012Publication date: March 13, 2014Applicants: IMMUNE DISEASE INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Kenneth R. Chien, Leon M. Ptaszek, Kathy Oi-Lan Lui, Lior Zangi, Wataru Ebina, Derrick J. Rossi